Immugenia Inc.
Developing the next generation CAR therapy using hemopoietic stem cells to treat cancer and prevent relapses.
Developing the next generation CAR therapy using hemopoietic stem cells to treat cancer and prevent relapses.
Immugenia Inc. is a preclinical stage immuno-oncology company founded in 2022, with a mission to develop the next generation CAR therapy for the treatment and prevention of relapses in hematological and solid tumors. The company's proprietary technology involves engineering hematopoietic stem cells using specific promoters (SPICA) to express CAR in select immune cells, ultimately leveraging the synergistic activity of T and NK cells. This innovative approach aims to provide patients with a one-and-done treatment solution for hard-to-treat cancers, effectively preventing relapses. Immugenia Inc. recently secured a Pre Seed Round investment on 06 October 2022 from notable investors including adMare BioInnovations, Sherbrooke Innopole, and ACET Capital. This funding will likely support the company's pioneering research and development efforts in the biotechnology industry, positioning them as a promising player in the evolving landscape of cancer therapeutics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Pre Seed Round | Unknown | 3 |
|
06 Oct 2022 |
No recent news or press coverage available for Immugenia Inc..
We care about your data, and we'd love to use cookies make your experience better.